381 related articles for article (PubMed ID: 1329273)
1. Post kala-azar dermal leishmaniasis in the Sudan: clinical features, pathology and treatment.
el Hassan AM; Ghalib HW; Zijlstra EE; Eltoum IA; Satti M; Ali MS; Ali HM
Trans R Soc Trop Med Hyg; 1992; 86(3):245-8. PubMed ID: 1329273
[TBL] [Abstract][Full Text] [Related]
2. Post-kala-azar dermal leishmaniasis in the Sudan: clinical presentation and differential diagnosis.
Zijlstra EE; Khalil EA; Kager PA; El-Hassan AM
Br J Dermatol; 2000 Jul; 143(1):136-43. PubMed ID: 10886148
[TBL] [Abstract][Full Text] [Related]
3. Post-kala-azar dermal leishmaniasis (PKDL): the first case report from Nepal.
Karki P; Koirala S; Parija SC; Sethi M; Das ML
Southeast Asian J Trop Med Public Health; 2003 Mar; 34(1):22-3. PubMed ID: 12971510
[TBL] [Abstract][Full Text] [Related]
4. Endemic kala-azar in eastern Sudan: post-kala-azar dermal leishmaniasis.
Zijlstra EE; el-Hassan AM; Ismael A
Am J Trop Med Hyg; 1995 Apr; 52(4):299-305. PubMed ID: 7741164
[TBL] [Abstract][Full Text] [Related]
5. Post kala azar dermal leishmaniasis in Sudan.
Kordofani YM; Nour YT; El-Hassan AM; Shalayel MH
East Mediterr Health J; 2001 Nov; 7(6):1061-4. PubMed ID: 15332749
[TBL] [Abstract][Full Text] [Related]
6. Post kala-azar dermal leishmaniasis: the Kenyan experience.
Muigai R; Gachihi GS; Oster CN; Were JB; Nyakundi PM; Chunge CN; Kirigi G; Rashid JR
East Afr Med J; 1991 Oct; 68(10):801-6. PubMed ID: 1667521
[TBL] [Abstract][Full Text] [Related]
7. Post-kala-azar dermal leishmaniasis (PKDL) developing after treatment of visceral leishmaniasis with amphotericin B and miltefosine.
Kumar D; Ramesh V; Verma S; Ramam M; Salotra P
Ann Trop Med Parasitol; 2009 Dec; 103(8):727-30. PubMed ID: 20030997
[No Abstract] [Full Text] [Related]
8. Post-kala-azar dermal leishmaniasis in the Sudan: peripheral neural involvement.
Elhassan AM; Ali MS; Zijlstra E; Eltoum IA; Ghalib HW; Ahmed HM
Int J Dermatol; 1992 Jun; 31(6):400-3. PubMed ID: 1512091
[TBL] [Abstract][Full Text] [Related]
9. Post-kala-azar dermal leishmaniasis mimicking leprosy: experience with 4 patients, with some unusual features in 1.
Dhar S; Kaur I; Dawn G; Sehgal S; Kumar B
Lepr Rev; 1995 Sep; 66(3):250-6. PubMed ID: 7500822
[TBL] [Abstract][Full Text] [Related]
10. Post-kala-azar dermal leishmaniasis--an unusual presentation.
Lakhanpal S; Pandhi RK; Khaitan BK
Acta Derm Venereol; 1998 Sep; 78(5):353-4. PubMed ID: 9779253
[TBL] [Abstract][Full Text] [Related]
11. Chronic Arsenic Exposure and Risk of Post Kala-azar Dermal Leishmaniasis Development in India: A Retrospective Cohort Study.
Das S; Mandal R; Rabidas VN; Verma N; Pandey K; Ghosh AK; Kesari S; Kumar A; Purkait B; Lal CS; Das P
PLoS Negl Trop Dis; 2016 Oct; 10(10):e0005060. PubMed ID: 27776123
[TBL] [Abstract][Full Text] [Related]
12. Cure of antimony-unresponsive Indian post-kala-azar dermal leishmaniasis with oral miltefosine.
Sundar S; Kumar K; Chakravarty J; Agrawal D; Agrawal S; Chhabra A; Singh V
Trans R Soc Trop Med Hyg; 2006 Jul; 100(7):698-700. PubMed ID: 16325873
[TBL] [Abstract][Full Text] [Related]
13. A case of Post-kala-azar dermal leishmaniasis.
Ono H; Ghoreishi M; Yokozeki H; Katayama I; Nishioka K
J Dermatol; 1998 Feb; 25(2):118-20. PubMed ID: 9563280
[TBL] [Abstract][Full Text] [Related]
14. IL-10- and TGF-beta-mediated susceptibility in kala-azar and post-kala-azar dermal leishmaniasis: the significance of amphotericin B in the control of Leishmania donovani infection in India.
Saha S; Mondal S; Ravindran R; Bhowmick S; Modak D; Mallick S; Rahman M; Kar S; Goswami R; Guha SK; Pramanik N; Saha B; Ali N
J Immunol; 2007 Oct; 179(8):5592-603. PubMed ID: 17911647
[TBL] [Abstract][Full Text] [Related]
15. Combination of sodium stibogluconate and rifampicin in post kala-azar dermal leishmaniasis.
Sharma VK; Prasad HR; Sethuraman G; Khaitan BK
Indian J Dermatol Venereol Leprol; 2007; 73(1):53-4. PubMed ID: 17314452
[No Abstract] [Full Text] [Related]
16. Changing clinico-epidemiology of post-kala-azar dermal leishmaniasis (PKDL) in India: Results of a survey in four endemic states.
Saurabh S; Roy P; Pandey DK; Ray D; Tarak S; Pandey R; Kumar D; Jamil S; Paulraj A; Kumar A; Dutta S
J Vector Borne Dis; 2020; 57(2):161-169. PubMed ID: 34290161
[TBL] [Abstract][Full Text] [Related]
17. Post kala-azar ocular leishmaniasis.
el Hassan AM; Khalil EA; el Sheikh EA; Zijlstra EE; Osman A; Ibrahim ME
Trans R Soc Trop Med Hyg; 1998; 92(2):177-9. PubMed ID: 9764325
[TBL] [Abstract][Full Text] [Related]
18. Post-kala-azar dermal leishmaniasis (PKDL), HIV and pulmonary tuberculosis.
Das VN; Pandey K; Verma N; Bimal S; Lal CS; Singh D; Das P
Natl Med J India; 2010; 23(2):88-9. PubMed ID: 20925205
[TBL] [Abstract][Full Text] [Related]
19. Short report: Development of post-kala-azar dermal leishmaniasis (PKDL) in miltefosine-treated visceral leishmaniasis.
Das VN; Pandey K; Verma N; Lal CS; Bimal S; Topno RK; Singh D; Siddiqui NA; Verma RB; Das P
Am J Trop Med Hyg; 2009 Mar; 80(3):336-8. PubMed ID: 19270277
[TBL] [Abstract][Full Text] [Related]
20. Distinguishing post-kala-azar dermal leishmaniasis from leprosy: experience in the Sudan.
el Hassan AM; Hashim FA; Abdullah M; Zijlstra EE; Ghalib HW
Lepr Rev; 1993 Mar; 64(1):53-9. PubMed ID: 8464317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
